Efficacy and Safety of Dapagliflozin-Vildagliptin in Indian T2DM Patients with CV Risk Factors - Video
|
Overview
The Fixed-Dose Combination (FDC) of Dapagliflozin 5 mg + Vildagliptin 50 mg demonstrated significant improvements in Glycemic Control, Metabolic parameters, and a favorable safety profile in Indian patients with Type 2 Diabetes Mellitus (T2DM) and Cardiovascular Risk Factors, according to a recent study published in the November 2025 issue of Cureus.
This retrospective, single-center study evaluated 101 T2DM patients prescribed the Dapagliflozin –Vildagliptin FDC over a three-month period. Of these, 49 patients completed the follow-up and were included in the final analysis. Patients were on existing antidiabetic therapy, with the FDC added as an add-on treatment.
Key findings of the study are:
1.Glycemic Control: Mean HbA1c decreased from 8.87% at baseline to 7.22%, a reduction of 1.65%. Fasting plasma glucose decreased by 68.14 mg/dL, and postprandial glucose dropped by 122.45 mg/dL, showing a pronounced post-meal glucose-lowering effect. The benefits were consistent across age groups, obesity status, disease duration, and comorbidities.
2.Metabolic Parameters: Total cholesterol, LDL-C, triglycerides, and HDL-C improved significantly. Liver enzymes ALT and AST also showed marked reductions, reflecting favorable hepatic outcomes.
3.Safety Profile: The FDC was well tolerated, with mild adverse events reported in a few patients, including gastrointestinal discomfort (2%), genitourinary infection (1.5%), and mild hypoglycemia (1.5%). No severe events, liver, or renal complications were observed.
Dapagliflozin 5 mg + Vildagliptin 50 mg FDC offers a safe and effective option for improving glycemic and metabolic outcomes in T2DM Patients with CV Risk Factors.
Adapted from:
Sanghvi A, Warrier S (November 18, 2025) Effectiveness and Safety of a Fixed-Dose Combination of Dapagliflozin and Vildagliptin in the Treatment of Type 2 Diabetes Mellitus: A Retrospective Study. Cureus 17(11): e97192. DOI 10.7759/cureus.97192
Speakers
Dr. Nandita Mohan is a practicing pediatric dentist with more than 5 years of clinical work experience. Along with this, she is equally interested in keeping herself up to date about the latest developments in the field of medicine and dentistry which is the driving force for her to be in association with Medical Dialogues. She also has her name attached with many publications; both national and international. She has pursued her BDS from Rajiv Gandhi University of Health Sciences, Bangalore and later went to enter her dream specialty (MDS) in the Department of Pedodontics and Preventive Dentistry from Pt. B.D. Sharma University of Health Sciences. Through all the years of experience, her core interest in learning something new has never stopped. She can be contacted at editorial@medicaldialogues.in. Contact no. 011-43720751